Natco Pharma has announced a board meeting scheduled for February 12, 2026, to review and approve the unaudited financial results for the quarter and period ended December 31, 2025. The board will also consider a potential 3rd interim dividend for the financial year ending 2025-26. The trading window for company securities is closed from January 29, 2026, to February 14, 2026, and will reopen on February 16, 2026.
Board Meeting Scheduled
Natco Pharma’s Board of Directors will convene on Thursday, February 12, 2026, to discuss and approve key financial matters. The meeting’s agenda includes a thorough review of the company’s financial performance for the recent period.
Financial Results and Dividend Consideration
The primary focus of the meeting will be the consideration of the unaudited financial results for the quarter and period concluding on December 31, 2025. Furthermore, the board will deliberate on the possibility of declaring a 3rd interim dividend for the financial year ending 2025-26. This decision will be based on the company’s financial standing and performance.
Trading Window Closure
In accordance with regulations regarding insider trading, the trading window for dealing in the company’s securities is currently closed. This restriction applies to employees, connected individuals, and their immediate family members. The closure began on January 29, 2026, and will remain in effect until February 14, 2026. Trading will resume on February 16, 2026.
Source: BSE
